FierceBiotech10h
PTC axes utreloxastat program after phase 2 ALS failure
But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show if twice daily oral dosing of ...
37-year-old artist with ALS creates moving portraits of people with the fatal disease
Philadelphia dad Eric Brunner was diagnosed with amyotrophic lateral sclerosis, the fatal disease known as ALS. He wants to ...
IIT-BHU developing med device with potential to cure sclerosis
A team from IIT-BHU is developing a revolutionary cell-based device using 3D bioprinting technology to potentially cure ...
FierceBiotech7h
PTC sells priority review voucher from Kebilidi approval for $150M
PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...
1PTCT : PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative...
PTC Therapeutics halts Utreloxastat development after ALS trial disappoints. Analysts highlight promising pipeline, including ...
Live Science on MSN1d
'Exercise juice' released by muscles helps nerves grow, study finds
In a new study of mouse cells, scientists found that both the biochemical and mechanical effects of exercise may help injured ...
PTC Therapeutics: Sell Rating Due to Unmet Trial Goals and Overvaluation Concerns
Bank of America Securities analyst Tazeen Ahmad maintained a Sell rating on PTC Therapeutics (PTCT – Research Report) yesterday and set a price ...
ALS News Today6h
Widetrial to manage physician network for ibudilast EAP
Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...
Neuralink wants its brain chip to control a robot arm next
There are now at least two patients who have had Neuralink's brain chip implanted in their head. While there have been some ...
IIT-BHU developing cell-based medical device for potential cure of Amyotrophic Lateral Sclerosis
A team at IIT (BHU) is developing a revolutionary cell-based medical device using 3D bioprinting technology aimed at curing ...
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...